WO2008035757A1 - Jelly-like food containing ubiquinol - Google Patents

Jelly-like food containing ubiquinol Download PDF

Info

Publication number
WO2008035757A1
WO2008035757A1 PCT/JP2007/068350 JP2007068350W WO2008035757A1 WO 2008035757 A1 WO2008035757 A1 WO 2008035757A1 JP 2007068350 W JP2007068350 W JP 2007068350W WO 2008035757 A1 WO2008035757 A1 WO 2008035757A1
Authority
WO
WIPO (PCT)
Prior art keywords
ubiquinol
jelly
food
ubiquinone
oil
Prior art date
Application number
PCT/JP2007/068350
Other languages
French (fr)
Japanese (ja)
Inventor
Hideyuki Kishida
Taizo Kawabe
Kazunori Hosoe
Original Assignee
Kaneka Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corporation filed Critical Kaneka Corporation
Priority to JP2008535395A priority Critical patent/JPWO2008035757A1/en
Publication of WO2008035757A1 publication Critical patent/WO2008035757A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L21/00Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
    • A23L21/10Marmalades; Jams; Jellies; Other similar fruit or vegetable compositions; Simulated fruit products
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/212Starch; Modified starch; Starch derivatives, e.g. esters or ethers
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a jelly food containing ubiquinol, which can be easily replenished with ubiquinol essential to a living body by ingesting it in the same way as normal food in daily life, and its use. It is.
  • Ubiquinol is a 2-electron reductant of ubiquinone, a benzoquinone derivative widely distributed in the living world.
  • Ubiquinol and ubiquinone are localized in mitochondria, lysosomes, Golgi bodies, microsomes, peroxisomes, or cell membranes, and are involved in ATP production activation, in vivo antioxidant action, and membrane stabilization as components of the electron transport system. It is an indispensable substance for maintaining the functions of living bodies.
  • Ubiquinone is also called vitamin Q because of its vitamin-like function, and is a component that rejuvenates the body as a nutrient source that restores weak cellular activity to a healthy state.
  • ubiquinol and ubiquinone In vivo, ubiquinol and ubiquinone have a certain equilibrium relationship, and ubiquinol / ubiquinone absorbed in the living body is known to be mutually oxidized / reduced. Normally, it is said that 60 to 90% of the total weight of ubiquinol and ubiquinone is present as ubiquinol in the living body! /.
  • the ubiquinone content in human heart is reported to be 11.0 g / g between the ages of 19 and 21, compared with 47.2 g / g between ages 77 and 81.
  • Non-Patent Document 1 plasma ubiquinone content in uremia and chronic hemodialysis patients and various allergic patients is reduced compared to healthy individuals.
  • Non-patent Document 4 plasma ubiquinone content in uremia and chronic hemodialysis patients and various allergic patients is reduced compared to healthy individuals.
  • the ubiquinone content of the LDL cholesterol fraction is reduced (Non-patent document 4).
  • ubiquinone has an effect of improving or preventing heart disease, hypertension, obesity, diabetes, cancer, Parkinson's disease, periodontal disease, neurological disease, allergy, fertility, motor ability, immune function, fatigue, etc. Expected.
  • Non-patent document 6 ubiquinone administration has been reported to increase cardiac function
  • ubiquinone has an effect to improve cardiac diseases such as congestive heart failure, angina pectoris, and myocardial infarction
  • Non-patent document 7 Non-patent document 8
  • arteriosclerosis hypertension
  • diabetes cancer
  • periodontal disease allergy, etc.
  • Non-patent document 9, Non-patent document 10, Non-patent document 11, Non-patent document 12 Fertility It is known to have an improving effect, an inhibition of LDL cholesterol oxidation, an effect of reducing the number of dialysis in renal dialysis patients, and an effect of enhancing nonspecific immunity (Non-patent Document 13, Non-Patent Document 14).
  • Ubiquinone is already used as a treatment for palpitations, shortness of breath, and swelling due to congestive heart failure or mild heart disease.
  • ubiquinol In addition to taking ubiquinol in this way, its strength is expected to be useful. In order to increase the absorption, ubiquinol as such is dissolved in oils and fats, and in some cases, surfactants are also added, and it is generally taken as a capsule to prevent oxidation. Is. However, in the case of capsules, they are difficult to take for people with low swallowing ability, such as the elderly and the sick!
  • ubiquinol-enriched oil-and-fat-containing foods have been reported as foods containing ubiquinol S, in order to include ubiquinol, a fat-soluble substance, in foods.
  • Ubiquinol is dissolved or coexisting in fats and oils.
  • Patent Document 1 JP-A-10-109933
  • Patent Document 2 JP-A-10-330251
  • Patent Document 3 WO03 / 061395
  • Non-Patent Document 1 Lipids, 24, 579-584 (1989)
  • Non-Patent Document 2 N mark hron, 66, 153-156 (1994)
  • Non-Patent Document 3 BioFactors, 1, 303-306 (1988)
  • Non-Patent Document 4 Atherosclerosis, 129, 119-126 (1997)
  • Non-Patent Document 5 Clinical Investigator, 71, S97-S102 (1993)
  • Non-Patent Document 6 Clinical Investigator, 71, S71-S75 (1993)
  • Non-Patent Document 7 Inter. J. Cardiology, 68, 23-29 (1999)
  • Non-Patent Document 8 Cardiovasc. Drugs Ther., 12, 347-353 (1998)
  • Non-Patent Document 9 Atherosclerosis, 148, 275-282 (1999)
  • Non-Patent Document 10 Curr. Therap. Res., 51, 668-672 (1992)
  • Non-Patent Document 11 Journal of Oral Hygiene, 43, 667-672 (1993)
  • Non-Patent Document 12 Clinical and Research, 58, 1349-1352 (1981)
  • Non-Patent Document 13 Mol. Aspects Med., 18, S85-S103 (1997)
  • Non-Patent Document 14 ⁇ 1 Aspects Med., 15, S213-S219 (1994)
  • Non-Patent Document 15 Acta Diabetol., 42, 179-181 (2005)
  • the purpose of the present invention is to obtain ubiquinol, which is apt to be reduced or insufficient, in healthy people, even though it is indispensable for the living body by ingesting it in the same way as normal food in daily life. It can be replenished easily and efficiently even for people with lower swallowing ability, such as older people and sick people, and it is a problem in modern people's eating habits! ⁇ ⁇ To provide jelly-like foods and their uses.
  • the present inventors use a gelling agent in place of fats and oils to make a jelly form, whereby ubiquinol can be stably and uniformly dispersed and a jelly-like food with excellent absorbability can be obtained. I found out for the first time. Such jelly-like foods are swallowing ability such as elderly and sick It is also useful for people who have fallen. That is, the present invention is as follows.
  • One or more gels selected from the group consisting of agar, gelatin, konjac flour, pectin, starch starch, katsu starch, bran starch, tapio force starch and carrageenan as a gelling agent [1] or [2] jelly, characterized by using an agent
  • Viscosity is 5.0 X 10 2 —1.0 X 10 5 mPa 's and / or hardness is 5 X 10 4 N / m 2 or less [1] to [3] Food.
  • the jelly-like food of the present invention can be consumed in the same way as normal food in daily life.
  • it is also a problem in the dietary habits of modern people who can easily and efficiently replenish even those with reduced swallowing ability such as elderly people and sick people! / Low calorie favorable for excessive energy Food.
  • the jelly-like food of the present invention is characterized by containing ubiquinol.
  • the ubiquinol contained may be substantially ubiquinol alone or a mixture of ubiquinone and ubiquinol.
  • the ratio is not particularly limited, but it is preferable that the content of ubiquinol is high! /, So that the weight ratio of ubiquinol / ubiquinone. 40/60 or more is preferred 60/40 or more is more preferred 80/20 is more preferred 95/5 is more preferred 99/1 is most preferred.
  • the ubiquinol used in the present invention may be produced by any known method such as a synthesis method or a fermentation method. However, if careful consideration is given to safety for living organisms, it can be used for foods such as meat and fish.
  • “derived from the fermentation method” means that the preferred stereoisomerism is obtained based on the fermentation method, for example, the (aU-E) -isomer of the (aU-E) -isomer obtained by the fermentation method. It does not prevent the conversion of ubiquinone and / or ubiquinol into a desired ratio of ubiquinol by treatments such as oxidation and reduction while maintaining its solid form. Stereoisomers are analyzed by HPLC by a conventional method.
  • ubiquinol used in the present invention is produced by using ubiquinone produced by a conventional method, preferably ubiquinone produced by fermentation, using sodium borohydride, sodium dithionite (hydrosulfite). This can be done by reducing by a conventional method using common reducing agents such as sodium) and zinc. After the reduction, crystallization may be concentrated by chromatography. Ubiquinol can be used whether it is solid, liquid, crystalline or amorphous.
  • the ratio of ubiquinone and ubiquinol is usually determined by quantifying the amount of ubiquinone and ubiquinol in a sample by an HPLC system using a UV detector, and calculating the ratio of the amounts. Using a system incorporating a mechanical detector, the ratio of ubiquinone and ubiquinol can be determined from the peak area. In systems incorporating electrochemical detectors, redox substances can be specifically measured and the sensitivity is high! Therefore, when measuring the proportion of ubiquinol present in a sample in a very small amount, Highly useful. Specifically, it can be measured under the following HPLC conditions by incorporating an electrochemical detector manufactured by Shiseido Co., Ltd. into an Shimadzu HPLC analyzer.
  • the jelly-like food of the present invention is not particularly limited as long as it is a food having a so-called gel-like form.
  • the jelly-like food is a jelly or a jelly-based food by a gelling agent such as gelatin, agar, or konjac. , Tapio power, warabimochi, litter, jam, boiled rice. Further, these gel-like compositions may have solids.
  • the material used for the jelly-like food of the present invention is not particularly limited as long as it has an appropriate viscosity added to a gel food raw material or a liquid food raw material.
  • the jelly-like food of the present invention is produced by using a gelling agent that is acceptable as a food and, if necessary, heat treatment or addition of water to form a gel or so-called jelly. Touch with force S.
  • the gelling agent used in the present invention is not particularly limited, and corn starch, potato starch, potato starch, sweet potato starch, katsu starch, potato starch (warabiko), tapio force starch, and other starches, agar , Gelatin, konjac flour (Darkmananan, galatatomannan), pectin, carrageenan, alginic acid and its salts, sirium, gum arabic, locust bean gum, guar gum, tamarind gum, quince seed gum, cara gum, tragacanth gum, gati gum, Xanthan gum, dielan gum (native dielan gum, deacyl type dielan gum), tara gum, arabinogalatatan, fur celerin, manolemero, curdlan, punoreran, dextran, canolepoxy methylenoresenorelona And cellulose derivatives such as Li ⁇ -time, and the like.
  • Starches agar, gelatin, konjac flour, and pectin are preferable. More preferred are agar, gelatin, konjac flour, pectin, kataguri starch, katsu starch, bran starch, tapio force starch. Two or more of these gelling agents do not work.
  • the jelly-like food of the present invention is not particularly limited as long as it has a shape and physical properties similar to an elastic semi-solid, so-called jelly or jelly-like beverage. It is preferable to have a viscosity of 5.0 ⁇ 10 2 mPa ′s or more under the temperature condition at the time of ingestion, and the upper limit thereof is preferably 1.0 ⁇ 10 5 mPa ′s or less.
  • the hardness is more preferably 5 ⁇ 10 4 N / m 2 or less, which is preferably 6 ⁇ 10 4 N / m 2 or less.
  • viscosity means “a material constant indicating the difficulty of liquid flow or the degree of viscosity”, which is referred to as viscosity or viscosity. Viscosity is the property that resists the force of squeezing when friction is applied to the inside when it is applied.
  • Hardness here refers to "resistance when compressed at a constant speed”. When a local force (concentrated load) is applied to a substance from outside in a short time, the degree of deformation of the substance indicated at that time is shown. The strength of the resistance against the resultant deformation is determined as hardness. [0030] The viscosity and hardness of food can be measured using a commercially available viscometer (rheometer, creep meter, etc.).
  • the jelly-like food according to the present invention can be used as a food for dysphagia and as a dietary supplement.
  • the number of elderly people with movement disorders such as bedridden 'severe dementia' and sequelae of stroke is increasing. If the swallowing function is impaired, food and beverages cannot be swallowed normally, and aspiration that is accidentally drawn into the trachea can lead to death of asphyxia and aspiration pneumonia! is there.
  • a liquid with a low viscosity like water is most easily swallowed by healthy people, but it is known that a person who has difficulty swallowing is less likely to cause aspiration. Food is used. Naturally, the hardness of the food is also important, and if it is not soft enough, it will be difficult to knead and mix.
  • the method for adjusting to the target viscosity and hardness is not particularly limited, and the type and amount of the gelling agent are adjusted, and other thickeners are used as appropriate.
  • a known method can be used.
  • gelatin and agar or carrageenan are used as a gelling agent, or carrageenan and xanthan gum are used.
  • the method includes using native dielan gum in combination.
  • An antioxidant, an organic acid, and vitamins may be added to the jelly-like food of the present invention.
  • Antioxidants include lycopene, carotenoids, flavonoids, polyphenols, dartathione, selenium, sodium thiosulfate, alpha lipoic acid and its derivatives, pycnogenol, flavangenol, superoxide dismutase (SOD) Glutathione peroxidase, dartathione S transferase, dartathione reductase, force tarase, ascorbate peroxidase, and mixtures thereof.
  • SOD superoxide dismutase
  • This antioxidants are used as particularly preferred additives from the viewpoint of enhancing the stability of ubiquinol to oxidation and obtaining a more stable and high effect.
  • the organic acid is not particularly limited, but examples thereof include succinic acid, succinic acid derivatives, acetic acid, lactic acid, succinic acid, tartaric acid, aspartic acid, oxalic acid, malic acid, malonic acid, fumaric acid, maleic acid, Examples include propionic acid, butyric acid, valeric acid, isochenoic acid, and mixtures thereof.
  • Organic acids are preferred in that they can add an appropriate flavor to the jelly-like food of the present invention, which is not only a component useful for the body itself.
  • the vitamins are not particularly limited.
  • vitamin A vitamin B (vitamin Bl, vitamin B1 derivative, vitamin B2, vitamin B6, vitamin B12, etc.), vitamin C, vitamin D, vitamins, vitamins , Biotin, pantothenic acid, nicotinic acid, and mixtures thereof.
  • the vitamin B1 derivative includes thiamine or a salt thereof, thiamine disulfide, fursultiamine or a salt thereof, dicetiamine, bisbuthiamine, bisbentiamine, benfotiamine, thiamine monophosphate disulfide, chicotiamine, otato thiamine, All of the compounds having physiological activity as vitamin B1, such as prosultiamine, can be included.
  • antioxidants organic acids, and vitamins may be used in combination of two or more.
  • ingredients contained in the jelly-like food of the present invention are not particularly limited as long as they are ingredients that can be used in foods. If necessary, sugars, sweeteners, fruit juices, flavor powders, flavors, antiseptics Agents, colorants, preservatives, etc. can be used.
  • the saccharide is not particularly limited, and examples thereof include sucrose, glucose, fructose, lactose, maltose, isomerized sugar, coupling sugar, palatinose, neosugar, reduced starch saccharified starch, xylose, sorbose, lactulose, poly And water-soluble saccharides such as dextrose, and mixtures thereof.
  • the sweetener is not particularly limited, and examples thereof include saccharin sodium, aspartame, stevioside, stevia extract, paramethoxycinnamic aldehyde, neohesperidyl dihydrochalcone, perilartin, and mixtures thereof.
  • the fruit juice is not particularly limited, and examples thereof include apple juice, orange juice, grape juice, melon juice, lemon juice and the like.
  • the flavor powder is not particularly limited, and for example, coffee powder, matcha powder, sencha powder, cocoa powder and the like are used.
  • the fragrance is not particularly limited, and examples thereof include menthol, carvone, vanetol, cineol, methyl salicylate, cinnamic aldehyde, eugenol, 3 (1-menthoxy) pronone 1, 2-dionole, and chimole.
  • Linalool Linalool, linalino acetate, limonene, menton, menthyl acetate, N-substituted paramentan 1-carboxamide, vinylene, octanolenodehydride, citral, pregon, carbyl acetate, anisaldehyde, ethyl acetate, ethyl butyrate , Allylcyclohexanepropionate, methylanthranilate, ethinoremethinoreethino glycidate, nonylin, undecalactone, hexananol, ethinoreanoreconole, propinoreanoreconole, butanol Single-flavored products such as soaminoleanolecole, hexenol, dimethylsulfide, cycloten, furfural, trimethylvirazone, ethyllatatate, ethylthi
  • the preservative is not particularly limited, and examples thereof include aminoethylsulfonic acid, benzoic acid, sodium benzoate, ethanol, sodium edetate, agar, dl-camphor, citrate, sodium citrate, salicylic acid, Sodium salicylate, phenyl salicylate, dibutylhydroxytoluene, sorbic acid, potassium sorbate, nitrogen, dehydroacetic acid, sodium dehydroacetate, 2-naphthol, sucrose, honey, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, ethyl paraoxybenzoate , Butyl paraoxybenzoate Propyl parabenzoate, methyl paraoxybenzoate, 1 menthol, eucalyptus oil, and mixtures thereof.
  • the colorant is not particularly limited, and it is possible to use one that is permitted to be added to food, for example, Blue No. 1, Yellow No. 4, Green No. 3, Red No. 5, Lake Examples thereof include dyes, titanium dioxide, red cabbage dyes, red potato dyes, purple potato dyes, gardenia dyes, cochineal dyes, caramel dyes, chlorophylls, and mixtures thereof.
  • the preservative is not particularly limited.
  • benzoic acid sodium benzoate, ethanol, sodium edetate, dried sodium sulfite, citrate, glycerin, salicylic acid, sodium salicylate, dibutylhydroxytoluene, D sorbitol , Sorbic acid, potassium sorbate, sodium dehydroacetate, isoptyl noroxybenzoate, isopropyl noroxybenzoate, ethyl parabenzoate, butyl parabenzoate, propyl parabenzoate, methyl paraoxybenzoate, propylene glycol , Phosphoric acid, and mixtures thereof.
  • the jelly-like food of the present invention may contain a slight amount of fat and oil components.
  • the amount of fat used is preferably 10% by weight or less, and preferably 5% by weight or less, based on the total amount of food. More preferably, it is 1% by weight or less, more preferably less than 0.5% by weight.
  • ubiquinol can be suitably dispersed in the food, so that the content of fat and oil relative to ubiquinol in the food can be, for example, equal or less, and even less than half. Is not included at all!
  • the jelly-like food of the present invention is a general food, as a dietary supplement and a health food, and is low in ubiquinol for not only healthy subjects but also elderly people and sick people with some disease. Can be consumed as a calorie food. Furthermore, it is also useful as a supplement for elderly and sick people with dysphagia. Furthermore, it can also be applied to animals such as pets, which have been difficult to consume in the past.
  • a cup or the like In addition to being provided as a jelly loaded in a bag or as a jelly-like beverage filled in a bouch or the like, the user can also prepare a jelly-like powder by cooking such as water and / or heating. Provided as a solid form.
  • the amount of the jelly-like food of the present invention is not particularly limited, but the daily dose for adults is lmg to;! OOOmg, preferably 10mg to 500mg, more preferably 30mg to 300mg. .
  • a lOOOOg ethanol solution, lOOg liquor, quinone (purity 99.4%) and 60 g L-asconolevic acid were added, and the mixture was stirred at 78 ° C. to carry out a reduction reaction. After 30 hours, the mixture was cooled to 50 ° C, and 330 g of ethanol and 70 g of water were added while maintaining the same temperature. While stirring this ethanol solution (containing ubiquinol lOOg), it was cooled to 2 ° C. at a cooling rate of 10 ° C./hour to obtain a white slurry.
  • the obtained slurry was filtered under reduced pressure, and the wet crystals were washed with cold ethanol, cold water and cold ethanol in this order (the temperature of the cold solvent used for washing was 2 ° C), and the wet crystals were further dried under reduced pressure (20-40 ° C). C,;! To 30 mmHg) to obtain 97 g of white dry crystals. All operations except drying under reduced pressure were performed under a nitrogen atmosphere.
  • lOOg ubiquinone (purity 99.4%) was dissolved in lOOOg heptane solution at 25 ° C. While stirring, sodium hyposulfite (purity of 75% or more) as a reducing agent was gradually added an aqueous solution prepared by adding 1000 ml of water to lOOg, and a reduction reaction was performed at 25 ° C and pH 4-6. After 2 hours, the aqueous phase was removed from the reaction solution, and the heptane phase was washed 6 times with degassed saturated saline lOOOg. As described above, all operations were performed in a nitrogen atmosphere.
  • This heptane phase was subjected to solvent replacement under reduced pressure to prepare a 7% (w / w) ethanol solution of ubiquinol at 50 ° C (containing lOOg of ubiquinol). 50 g of water was added to the ethanol solution, and while stirring, the solution was cooled to 2 ° C. at a cooling rate of 10 ° C./hour to precipitate crystals. All operations are nitrogen Performed under atmosphere. The obtained slurry was filtered under reduced pressure, and the wet crystals were cooled with cold ethanol and cold water.
  • a model sample obtained by drying a jelly-like food containing ubiquinol was prepared as follows.
  • oily components are separated by solid-liquid separation according to a conventional method, and the oily components adhering to the particles are washed and removed with about 500 g of ethanol, dried at 50 ° C, and ubiquinol is dispersed in gelatin.
  • a particulate composition (model sample of jelly-like food) was obtained.
  • This composition and the ubiquinol crystals of Production Example 1 were used for rats respectively.
  • An evaluation sample was packed in a capsule.
  • Cmax maximum plasma concentration of ubiquinone
  • AUC area under the time course curve of the concentration of ubiquinone
  • ubiquinol obtained in Production Example 1 was added and homogenized to obtain a ubiquinol-soluble material (emulsion). Next, heat while adding casein and dextrin to the previous emulsion, and add fructose-glucose liquid sugar, calcium lactate, citrate, fragrance, citrate Na, vitamins, and a cup-shaped container with sufficient stirring. The jelly-like food containing ubiquinol was obtained. The taste of the resulting jelly-like food was good.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)

Abstract

A jelly-like food containing ubiquinol. It is found out that ubiquinol can be stably and homogeneously dispersed by using a gelling agent as a substitute for a fat or the like. Thus, it becomes possible to easily and efficiently supply ubiquinol, which is essentially required by living bodies but frequently shows a tendency to decrease or shortage, not only to normal people but also to those having disorders in swallowing ability such as aged persons and ill persons. Because of having a low fat content, the above-described jelly-like food is advantageous for modern people with a tendency to take too much energy.

Description

明 細 書  Specification
ュビキノールを含有するゼリー状食品  Jelly-like food containing ubiquinol
技術分野  Technical field
[0001] 本発明は、 日常生活で通常の食品と同様に摂取することにより、生体に必要不可 欠なュビキノールを容易に補給することができる、ュビキノールを含有したゼリー状食 品及びその用途に関するものである。  [0001] The present invention relates to a jelly food containing ubiquinol, which can be easily replenished with ubiquinol essential to a living body by ingesting it in the same way as normal food in daily life, and its use. It is.
背景技術  Background art
[0002] ュビキノールは、広く生物界に分布するべンゾキノン誘導体であるュビキノンの 2電 子還元体である。ュビキノール及びュビキノンは、ミトコンドリア、リソゾーム、ゴルジ体 、ミクロソーム、ペルォキシソーム、或いは細胞膜などに局在し、電子伝達系の構成 成分として ATP産生賦活、生体内での抗酸化作用、膜安定化に関与している事が 知られている生体の機能維持に必要不可欠な物質である。ュビキノンについては、 そのビタミン様の機能からビタミン Qとも呼ばれており、弱った細胞活性を健康な状態 に戻す栄養源として身体を若返らせる成分である。  [0002] Ubiquinol is a 2-electron reductant of ubiquinone, a benzoquinone derivative widely distributed in the living world. Ubiquinol and ubiquinone are localized in mitochondria, lysosomes, Golgi bodies, microsomes, peroxisomes, or cell membranes, and are involved in ATP production activation, in vivo antioxidant action, and membrane stabilization as components of the electron transport system. It is an indispensable substance for maintaining the functions of living bodies. Ubiquinone is also called vitamin Q because of its vitamin-like function, and is a component that rejuvenates the body as a nutrient source that restores weak cellular activity to a healthy state.
[0003] 生体内でュビキノールとュビキノンはある種の平衡関係にあり、生体内に吸収され たュビキノール/ュビキノンは、相互に酸化/還元される事が知られている。通常、 生体内では、ュビキノールとュビキノンの合計重量に対し 60〜90%がュビキノール として存在して!/、ると言われて!/、る。  [0003] In vivo, ubiquinol and ubiquinone have a certain equilibrium relationship, and ubiquinol / ubiquinone absorbed in the living body is known to be mutually oxidized / reduced. Normally, it is said that 60 to 90% of the total weight of ubiquinol and ubiquinone is present as ubiquinol in the living body! /.
[0004] ュビキノンについては食事によって補給される一方、生体内でも生合成されている 事から、正常な状態ではュビキノン及びュビキノールの必要量は充足されて!/、るか に見えるが、これらの生体内での含量は加齢や生体が受ける種々のストレスにより顕 著に減少することが知られている。  [0004] While ubiquinone is replenished by meals, it is also biosynthesized in vivo, so it seems that the necessary amount of ubiquinone and ubiquinol is satisfied under normal conditions! It is known that the content in the body is markedly reduced by aging and various stresses on the body.
[0005] 例えば、ヒト心臓中ュビキノン含量は、 19歳〜 21歳の場合 110. 0 g/gであるの に対し、 77歳〜 81歳では 47. 2 g/gと半減することが報告されている(非特許文 献 1)。また、尿毒症及び慢性の血液透析患者、種々のアレルギー患者の血漿中ュ ビキノン含量は健常人に比較し減少している(非特許文献 2、非特許文献 3)。高脂 血症患者では、 LDLコレステロール画分のュビキノン含量が減少している(非特許文 献 4)。更に、昨今高コレステロール血漿治療剤として汎用されているコレステロール 合成阻害剤の投与が、ュビキノンの生合成をも阻害し、組織でのュビキノン濃度の低 下をもたらしていることが指摘されている(非特許文献 5)。更に、激しい運動や過労 時等、生体内で過酸化物が生成しやすい条件下においても、組織内濃度の減少が 推定されている。 [0005] For example, the ubiquinone content in human heart is reported to be 11.0 g / g between the ages of 19 and 21, compared with 47.2 g / g between ages 77 and 81. (Non-Patent Document 1). In addition, plasma ubiquinone content in uremia and chronic hemodialysis patients and various allergic patients is reduced compared to healthy individuals (Non-patent Documents 2 and 3). In patients with hyperlipidemia, the ubiquinone content of the LDL cholesterol fraction is reduced (Non-patent document 4). Furthermore, it has been pointed out that administration of a cholesterol synthesis inhibitor, which is currently widely used as a therapeutic agent for high cholesterol plasma, also inhibits the biosynthesis of ubiquinone, resulting in a decrease in the concentration of ubiquinone in tissues (non-) Patent Document 5). Furthermore, it is estimated that the concentration in the tissue decreases even under conditions where peroxides are easily generated in vivo, such as during intense exercise or overwork.
[0006] 生体内ュビキノール及びュビキノン含量の低下は、その特性上、 ATP産生力の減 退、心機能の減退、酸化ストレスに対する抵抗性の減退、生体膜の不安定化をもたら し、健康上好ましくない。不足しているュビキノール及びュビキノンを補給することは 、ミトコンドリアでのエネルギー産生促進及び生体の抗酸化能を向上し恒常性を維持 するために有益である。  [0006] Decreased contents of ubiquinol and ubiquinone in vivo lead to a decrease in ATP productivity, a decrease in cardiac function, a decrease in resistance to oxidative stress, and a destabilization of biological membranes. It is not preferable. Supplementing deficient ubiquinol and ubiquinone is beneficial for promoting energy production in mitochondria and improving the antioxidant capacity of the body and maintaining homeostasis.
[0007] ュビキノンには、例えば、心疾患、高血圧、肥満、糖尿病、癌、パーキンソン病、歯 周病、神経疾患、アレルギー、生殖能、運動能、免疫機能、疲労等の改善や予防の 効果が期待されている。  [0007] For example, ubiquinone has an effect of improving or preventing heart disease, hypertension, obesity, diabetes, cancer, Parkinson's disease, periodontal disease, neurological disease, allergy, fertility, motor ability, immune function, fatigue, etc. Expected.
[0008] 例えば、ュビキノン投与による心機能の亢進が報告されており(非特許文献 6)、ュ ビキノンによる鬱血性心不全、狭心症、心筋梗塞などの心疾患の改善効果 (非特許 文献 7、非特許文献 8)、動脈硬化、高血圧、糖尿病、癌、歯周病、アレルギーなどの 予防 ·改善効果 (非特許文献 9、非特許文献 10、非特許文献 11、非特許文献 12)、 生殖能向上効果、 LDLコレステロールの酸化抑制、腎透析患者での透析回数の減 少効果、非特異的免疫能の増強効果等が知られている (非特許文献 13、非特許文 献 14)。また、ュビキノンは既に、鬱血性心不全或いは軽度な心疾患による動悸、息 切れ、むくみの治療薬として利用されている。  [0008] For example, ubiquinone administration has been reported to increase cardiac function (Non-patent document 6), and ubiquinone has an effect to improve cardiac diseases such as congestive heart failure, angina pectoris, and myocardial infarction (Non-patent document 7, Non-patent document 8), prevention and improvement of arteriosclerosis, hypertension, diabetes, cancer, periodontal disease, allergy, etc. (Non-patent document 9, Non-patent document 10, Non-patent document 11, Non-patent document 12), Fertility It is known to have an improving effect, an inhibition of LDL cholesterol oxidation, an effect of reducing the number of dialysis in renal dialysis patients, and an effect of enhancing nonspecific immunity (Non-patent Document 13, Non-Patent Document 14). Ubiquinone is already used as a treatment for palpitations, shortness of breath, and swelling due to congestive heart failure or mild heart disease.
[0009] 日々の生活にお!/、て低下する生体内ュビキノール及びュビキノン含量を補うため は適度にュビキノールやュビキノンを補給することが必要である。中高年はもとより、 若い人でも、過度の運動時に指摘されるような酸化ストレス障害の場合は、特にュビ キノール含量が低下するので、ュビキノールを補給して生体の抗酸化能を上げてお くことは大切である。生体内のュビキノール含量を向上させるために、外来的にュビ キノンを補給する方法が従来より用いられてきた。  [0009] In order to compensate for the in vivo ubiquinol and ubiquinone contents that decrease in daily life !, it is necessary to appropriately supplement ubiquinol and ubiquinone. Even in middle-aged and young people, ubiquinol content decreases especially in the case of oxidative stress disorder that is pointed out during excessive exercise, so supplement ubiquinol to increase the antioxidant capacity of the living body. Is important. In order to improve the ubiquinol content in the living body, an exogenous method for supplementing ubiquinone has been used.
[0010] 上記の様に生体の機能維持に必要不可欠で、 日々の生活において減少 '不足し 力 Sちなュビキノンを補給する方法として、錠剤、カプセル剤の形態で医薬として、或 いはサプリメントとして補給する方法が既に実施されて!/、るが、不足の度合!/、が軽度 で医療の対象とならない健康人、或いは半健康人等にとって、錠剤やカプセル剤と して摂取するよりも、通常の食品と同様に摂取する方が簡便である。 [0010] As described above, it is indispensable for maintaining the functions of the living body, and it is decreasing and lacking in daily life. As a method of replenishing ubiquinone, a method of replenishing as a medicine or supplement in the form of tablets or capsules has already been implemented! / However, the degree of deficiency! / For healthy and semi-healthy people who are not the target, it is easier to ingest like normal foods than to ingest as tablets or capsules.
[0011] この様に、ュビキノンを含有した食品を利用すれば、生体内でュビキノンとュビキノ ールは平衡関係にあるので、ュビキノンそのものだけでなく不足しがちなュビキノー ルの補給が容易に可能になると考えられてきた。しかしながら、近年、種々の用途に ぉレ、て、ュビキノールを摂取することがュビキノンを摂取することよりも有効であるとの 報告がなされている。例えば、ュビキノールがュビキノンよりも経口吸収性に優れて いること(特許文献 1 )や、高コレステロール血症、高脂血症や動脈硬化症の改善'予 防に効果があること(特許文献 2)が報告されている。また、高齢者や病人ではュビキ ノンをュビキノールに還元する能力が弱くなるとの報告もある(非特許文献 15)。 [0011] In this way, if a food containing ubiquinone is used, ubiquinone and ubiquinol are in an equilibrium relationship in vivo, so it is possible to easily replenish not only ubiquinone itself but also ubiquinol, which tends to be insufficient. Has been considered to be. However, in recent years, it has been reported that taking ubiquinol is more effective than taking ubiquinone for various purposes. For example, ubiquinol has better oral absorption than ubiquinone (Patent Document 1), and is effective in preventing or preventing hypercholesterolemia, hyperlipidemia and arteriosclerosis (Patent Document 2). Has been reported. In addition, there is a report that the ability to reduce ubiquinone to ubiquinol is weakened in the elderly and sick (Non-patent Document 15).
[0012] このようにュビキノールを摂取することはその有用性が期待されている力 ュビキノ ールが非常に酸化されやすレ、とレ、う性質を有して!/、ることに加えて、ュビキノールそ のままでは吸収性が低ぐ吸収性を上げるためには油脂等に溶解し、さらに場合によ つては界面活性剤なども添加し、酸化を防ぐためにカプセル剤として摂取されるのが 一般的である。し力もながらカプセル剤の場合、高齢者や病人など嚥下能力の低い 人にとっては摂取しにくいと!/、う問題がある。  [0012] In addition to taking ubiquinol in this way, its strength is expected to be useful. In order to increase the absorption, ubiquinol as such is dissolved in oils and fats, and in some cases, surfactants are also added, and it is generally taken as a capsule to prevent oxidation. Is. However, in the case of capsules, they are difficult to take for people with low swallowing ability, such as the elderly and the sick!
[0013] またュビキノールを含有する食品として、ュビキノールを富化した油脂含有食品(特 許文献 3)が報告されている力 S、ここでは、脂溶性物質であるュビキノールを食品に含 有させるために、ュビキノールを油脂等に溶解あるいは共存させて使用している。  [0013] In addition, ubiquinol-enriched oil-and-fat-containing foods (Patent Document 3) have been reported as foods containing ubiquinol S, in order to include ubiquinol, a fat-soluble substance, in foods. , Ubiquinol is dissolved or coexisting in fats and oils.
[0014] 上述したように、ュビキノールの摂取においては、従来、油脂や界面活性剤などと 同時に摂取する方法が一般的である。油脂 (脂肪)は 3大栄養素の 1種であり、エネ ルギ一源として重要であると同時に、食品に対するなめらかな食感の付与、こくづけ 、濃厚感の付与等の機能を持つ。しかし、最近では肥満や生活習慣病への関心の 高まりから、食品中の高カロリー物質である脂肪の摂取量を低減化することが求めら れている。  [0014] As described above, in the intake of ubiquinol, conventionally, a method of taking in at the same time as fats and oils, surfactants, and the like is common. Oils and fats (fats) are one of the three macronutrients and are important as a source of energy, and at the same time have functions such as imparting a smooth texture to food, imparting richness, and so on. However, recently, with increasing interest in obesity and lifestyle-related diseases, it has been required to reduce the intake of fat, which is a high calorie substance in foods.
特許文献 1 :特開平 10— 109933 特許文献 2 :特開平 10— 330251 Patent Document 1: JP-A-10-109933 Patent Document 2: JP-A-10-330251
特許文献 3 : WO03/061395  Patent Document 3: WO03 / 061395
非特許文献 1 : Lipids, 24, 579-584 (1989)  Non-Patent Document 1: Lipids, 24, 579-584 (1989)
非特許文献 2 : N印 hron, 66, 153-156 (1994)  Non-Patent Document 2: N mark hron, 66, 153-156 (1994)
非特許文献 3 : BioFactors, 1, 303-306 (1988)  Non-Patent Document 3: BioFactors, 1, 303-306 (1988)
非特許文献 4 : Atherosclerosis, 129, 119-126 (1997)  Non-Patent Document 4: Atherosclerosis, 129, 119-126 (1997)
非特許文献 5: Clinical Investigator, 71, S97-S102 (1993)  Non-Patent Document 5: Clinical Investigator, 71, S97-S102 (1993)
非特許文献 6: Clinical Investigator, 71, S71-S75 (1993)  Non-Patent Document 6: Clinical Investigator, 71, S71-S75 (1993)
非特許文献 7 : Inter. J. Cardiology, 68, 23-29 (1999)  Non-Patent Document 7: Inter. J. Cardiology, 68, 23-29 (1999)
非特許文献 8: Cardiovasc. Drugs Ther., 12, 347-353 (1998)  Non-Patent Document 8: Cardiovasc. Drugs Ther., 12, 347-353 (1998)
非特許文献 9 : Atherosclerosis, 148, 275-282 (1999)  Non-Patent Document 9: Atherosclerosis, 148, 275-282 (1999)
非特許文献 10 : Curr. Therap. Res., 51, 668-672 (1992)  Non-Patent Document 10: Curr. Therap. Res., 51, 668-672 (1992)
非特許文献 11 :口腔衛生学会誌, 43, 667-672 (1993)  Non-Patent Document 11: Journal of Oral Hygiene, 43, 667-672 (1993)
非特許文献 12 :臨床と研究, 58, 1349-1352(1981)  Non-Patent Document 12: Clinical and Research, 58, 1349-1352 (1981)
非特許文献 13 : Mol. Aspects Med., 18, S85- S103 (1997)  Non-Patent Document 13: Mol. Aspects Med., 18, S85-S103 (1997)
非特許文献 14 : Μο1· Aspects Med., 15, S213- S219 (1994))  (Non-Patent Document 14: Μο1 Aspects Med., 15, S213-S219 (1994))
非特許文献 15 : Acta Diabetol., 42, 179-181 (2005)  Non-Patent Document 15: Acta Diabetol., 42, 179-181 (2005)
発明の開示  Disclosure of the invention
発明が解決しょうとする課題  Problems to be solved by the invention
[0015] 本発明の目的は、 日常生活で通常の食品と同様に摂取することにより、生体に必 要不可欠であるにも関わらず、減少 ·不足しがちなュビキノールを、健常な人はもとよ り高齢者や病人など嚥下能力の低下した人にとっても容易に且つ効率良く補給する ことができ、現代人の食生活で問題となって!/、るエネルギー過多に対しても好まし!/ヽ ゼリー状食品及びその用途を提供することにある。  [0015] The purpose of the present invention is to obtain ubiquinol, which is apt to be reduced or insufficient, in healthy people, even though it is indispensable for the living body by ingesting it in the same way as normal food in daily life. It can be replenished easily and efficiently even for people with lower swallowing ability, such as older people and sick people, and it is a problem in modern people's eating habits!あ る To provide jelly-like foods and their uses.
課題を解決するための手段  Means for solving the problem
[0016] 本発明者らは、油脂等に代えてゲル化剤を使用してゼリー状とすることにより、ュビ キノールを安定かつ均一に分散できてさらに吸収性にも優れたゼリー状食品となりう ることをはじめて見出した。そのようなゼリー状食品は、高齢者や病人など嚥下能力 の低下した人にとっても有用である。即ち、本発明は以下の通りである。 [0016] The present inventors use a gelling agent in place of fats and oils to make a jelly form, whereby ubiquinol can be stably and uniformly dispersed and a jelly-like food with excellent absorbability can be obtained. I found out for the first time. Such jelly-like foods are swallowing ability such as elderly and sick It is also useful for people who have fallen. That is, the present invention is as follows.
[0017] [1] ュビキノールを含有するゼリー状食品。 [0017] [1] A jelly-like food containing ubiquinol.
[2] ゼリー状とするためのゲル化剤を使用することを特徴とする [1]記載のゼリー状 ロ P〇  [2] A gelling agent for forming a jelly is used. The jelly described in [1]
[3] ゲル化剤として、寒天、ゼラチン、コンニヤク粉、ぺクチン、片栗でんぷん、葛で んぷん、蕨でんぷん(わらびこ)、タピオ力でんぷん及びカラギーナンからなる群より 選択される 1種以上のゲル化剤を使用することを特徴とする [1]又は [2]のゼリー状 [3] One or more gels selected from the group consisting of agar, gelatin, konjac flour, pectin, starch starch, katsu starch, bran starch, tapio force starch and carrageenan as a gelling agent [1] or [2] jelly, characterized by using an agent
^ PP o ^ PP o
[4] 粘度が 5.0 X 102—1.0 X 105 mPa' s、及び/又は、硬さが 5 X 104 N/m2以下で ある [1]〜 [3]レ、ずれかのゼリー状食品。 [4] Viscosity is 5.0 X 10 2 —1.0 X 10 5 mPa 's and / or hardness is 5 X 10 4 N / m 2 or less [1] to [3] Food.
[5] さらに有機酸を含有する [1]〜 [4] V、ずれかのゼリー状食品。  [5] Further containing an organic acid [1] to [4] V, any jelly-like food.
[6] さらに抗酸化剤を含有する [1]〜 [5] V、ずれかのゼリー状食品。  [6] Further containing an antioxidant [1] to [5] V, any jelly-like food.
[7] さらにビタミン類を含有する [1]〜 [6] V、ずれかのゼリー状食品。  [7] Further containing vitamins [1] to [6] V, some jelly-like food.
[8] 油脂の含有量が 0· 5重量%未満である [1]〜[7]いずれかのゼリー状食品。 発明の効果  [8] The jelly-like food according to any one of [1] to [7], wherein the fat content is less than 0.5% by weight. The invention's effect
[0018] 本発明のゼリー状食品は、 日常生活で通常の食品と同様に摂取することにより、生 体に必要不可欠であるにも関わらず、減少 ·不足しがちなュビキノールを、健常な人 はもとより高齢者や病人など嚥下能力の低下した人にとっても容易に且つ効率良く 補給することができるだけでなぐ現代人の食生活で問題となって!/、るエネルギー過 多に対しても好ましい低カロリーの食品である。  [0018] The jelly-like food of the present invention can be consumed in the same way as normal food in daily life. Of course, it is also a problem in the dietary habits of modern people who can easily and efficiently replenish even those with reduced swallowing ability such as elderly people and sick people! / Low calorie favorable for excessive energy Food.
発明を実施するための最良の形態  BEST MODE FOR CARRYING OUT THE INVENTION
[0019] 本発明のゼリー状食品は、ュビキノールを含有することを特徴とする。本発明のゼリ 一状食品において、含有されるュビキノールは、実質的にュビキノール単独であって もよく、又、ュビキノンとュビキノールの混合物であってもよい。本発明において、ュビ キノールとュビキノンの混合物を使用する場合、その割合は特に限定されないが、ュ ビキノールの含有量が高!/、ことが好まし!/、ことから、ュビキノール/ュビキノンの重量 比として、 40/60以上が好ましぐ 60/40以上がより好ましぐ 80/20がさらに好ま しぐ 95/5がよりさらに好ましぐ 99/1であるのがもっとも好ましい。 [0020] 本発明に使用するュビキノールは、合成法もしくは発酵法など、いかなる公知の方 法で製造されたものでもよいが、生体に対する安全性を慎重に配慮すれば、肉、魚 等の食品に含まれるものと同じ(aU-E)—異性体であるのが好ましぐこの場合、その 製造法が発酵法に由来するものが好ましい。ここで、「発酵法に由来する」とは、好ま しい上記立体異性が発酵法に基づき得られることを意味しており、例えば、発酵法に より得られた(aU-E)—異性体のュビキノン及び/又はュビキノールを、その立体を保 持したまま、酸化、還元等の処理により、所望の比率のュビキノールに変換することを 妨げない。尚、立体異性体は常法により HPLCにて分析される。 [0019] The jelly-like food of the present invention is characterized by containing ubiquinol. In the jelly-like food of the present invention, the ubiquinol contained may be substantially ubiquinol alone or a mixture of ubiquinone and ubiquinol. In the present invention, when a mixture of ubiquinol and ubiquinone is used, the ratio is not particularly limited, but it is preferable that the content of ubiquinol is high! /, So that the weight ratio of ubiquinol / ubiquinone. 40/60 or more is preferred 60/40 or more is more preferred 80/20 is more preferred 95/5 is more preferred 99/1 is most preferred. [0020] The ubiquinol used in the present invention may be produced by any known method such as a synthesis method or a fermentation method. However, if careful consideration is given to safety for living organisms, it can be used for foods such as meat and fish. Preferably the same (aU-E) -isomer as that contained, in which case the production method is preferably derived from the fermentation process. Here, “derived from the fermentation method” means that the preferred stereoisomerism is obtained based on the fermentation method, for example, the (aU-E) -isomer of the (aU-E) -isomer obtained by the fermentation method. It does not prevent the conversion of ubiquinone and / or ubiquinol into a desired ratio of ubiquinol by treatments such as oxidation and reduction while maintaining its solid form. Stereoisomers are analyzed by HPLC by a conventional method.
[0021] また、本発明に使用するュビキノールの製造は、常法で製造されたュビキノン、好 ましくは発酵法により製造されたュビキノンを、水素化ほう素ナトリウム、亜ジチオン酸 ナトリウム (ハイドロサルファイトナトリウム)、亜鉛等の一般的な還元剤を用いて、常法 により還元することにより行うこと力 Sできる。上記還元後は、晶析ゃクロマトグラフィー による濃縮を行っても良い。ュビキノールは、固体状であれ液状であれ、結晶状であ れ、アモルファス状であれ使用し得る。  [0021] In addition, ubiquinol used in the present invention is produced by using ubiquinone produced by a conventional method, preferably ubiquinone produced by fermentation, using sodium borohydride, sodium dithionite (hydrosulfite). This can be done by reducing by a conventional method using common reducing agents such as sodium) and zinc. After the reduction, crystallization may be concentrated by chromatography. Ubiquinol can be used whether it is solid, liquid, crystalline or amorphous.
[0022] ュビキノンとュビキノールの割合は、通常、 UV検出器を用いた HPLCシステムによ り、試料中のュビキノンとュビキノールを定量し、その量比をもって算出する方法、ま たは、 HPLCに電気化学的検出器を組み込んだシステムにより、ュビキノンとュビキ ノールの割合をピーク面積から算出する方法により求めることができる。電気化学的 検出器を組み込んだシステムでは、酸化還元物質を特異的に測れることおよび感度 が高!/、ことから、生体あるレ、は試料に微量に存在するュビキノールの割合を測定す る場合は、有用性が高い。具体的には、島津社製の HPLC分析装置に資生堂社製 の電気化学的検出器を組み込み、以下の HPLC条件で測定できる。  [0022] The ratio of ubiquinone and ubiquinol is usually determined by quantifying the amount of ubiquinone and ubiquinol in a sample by an HPLC system using a UV detector, and calculating the ratio of the amounts. Using a system incorporating a mechanical detector, the ratio of ubiquinone and ubiquinol can be determined from the peak area. In systems incorporating electrochemical detectors, redox substances can be specifically measured and the sensitivity is high! Therefore, when measuring the proportion of ubiquinol present in a sample in a very small amount, Highly useful. Specifically, it can be measured under the following HPLC conditions by incorporating an electrochemical detector manufactured by Shiseido Co., Ltd. into an Shimadzu HPLC analyzer.
[0023] カラム:丫^[じー?&。15(003—八303)、検出波長:2751 111、移動相:メタノール(8 8%)、へキサン(12%)、流速: lml/min。 [0023] Column: 丫 ^ [Ji? &. 1 5 (003—303), detection wavelength: 2751 111, mobile phase: methanol (88%), hexane (12%), flow rate: lml / min.
[0024] 本発明のゼリー状食品としては、いわゆるゲル状の形態を有する食品であれば特 に限定されないが、具体的には、ゼラチン、寒天、コンニヤクなどのゲル化剤によるゼ リーやゼリー寄せ、タピオ力、わらびもち、くず、ジャム、煮こごりなどが挙げられる。ま たこれらゲル状の組成物中に固形物を有しているものであってもかまわない。 [0025] 本発明のゼリー状食品に使用される材料としては、ゲル状の食品原料、または液状 の食品原料に適度な粘度を付加したものであれば特に限定されない。例えば、食品 として許容できるゲル化剤を使用して、必要であれば、加熱処理や加水などの処理 を行い、ゲル状、いわゆるゼリー状にすることによって、本発明のゼリー状食品を製造 すること力 Sでさる。 [0024] The jelly-like food of the present invention is not particularly limited as long as it is a food having a so-called gel-like form. Specifically, the jelly-like food is a jelly or a jelly-based food by a gelling agent such as gelatin, agar, or konjac. , Tapio power, warabimochi, litter, jam, boiled rice. Further, these gel-like compositions may have solids. [0025] The material used for the jelly-like food of the present invention is not particularly limited as long as it has an appropriate viscosity added to a gel food raw material or a liquid food raw material. For example, the jelly-like food of the present invention is produced by using a gelling agent that is acceptable as a food and, if necessary, heat treatment or addition of water to form a gel or so-called jelly. Touch with force S.
[0026] 本発明に用いられるゲル化剤としては特に限定されず、とうもろこしでんぷん、片栗 でんぷん、馬鈴薯でんぷん、さつまいもでんぷん、葛でんぷん、蕨でんぷん(わらび こ)、タピオ力でんぷん、などのでんぷん類、寒天、ゼラチン、コンニヤク粉(ダルコマ ンナン、ガラタトマンナン)、ぺクチン、カラギーナン、アルギン酸及びその塩、サイリウ ム、アラビアガム、ローカストビーンガム、グァーガム、タマリンドガム、クィンスシードガ ム、カラャガム、トラガントガム、ガッティ一ガム、キサンタンガム、ジエランガム(ネィテ ィブジエランガム、脱ァシル型ジエランガム)、タラガム、ァラビノガラタタン、ファーセレ ラン、マノレメロ、カードラン、プノレラン、デキストラン、カノレポキシメチノレセノレロースナトリ ゥム等のセルロース誘導体等が挙げられる。好ましくは、でんぷん類、寒天、ゼラチン 、コンニヤク粉、ぺクチンである。より好ましくは、寒天、ゼラチン、コンニヤク粉、ぺクチ ン、片栗でんぷん、葛でんぷん、蕨でんぷん(わらびこ)、タピオ力でんぷんである。こ れらのゲル化剤は 2種以上組み合わせても力、まわない。  [0026] The gelling agent used in the present invention is not particularly limited, and corn starch, potato starch, potato starch, sweet potato starch, katsu starch, potato starch (warabiko), tapio force starch, and other starches, agar , Gelatin, konjac flour (Darkmananan, galatatomannan), pectin, carrageenan, alginic acid and its salts, sirium, gum arabic, locust bean gum, guar gum, tamarind gum, quince seed gum, cara gum, tragacanth gum, gati gum, Xanthan gum, dielan gum (native dielan gum, deacyl type dielan gum), tara gum, arabinogalatatan, fur celerin, manolemero, curdlan, punoreran, dextran, canolepoxy methylenoresenorelona And cellulose derivatives such as Li ©-time, and the like. Starches, agar, gelatin, konjac flour, and pectin are preferable. More preferred are agar, gelatin, konjac flour, pectin, kataguri starch, katsu starch, bran starch, tapio force starch. Two or more of these gelling agents do not work.
[0027] 本発明のゼリー状食品は、弾性のある半固体の、いわゆるゼリーやゼリー状飲料に 類する形状や物性を有しているものであれば特に限定されないが、例えば、その粘 度としては、摂取時の温度条件下で、 5.0 X 102 mPa' s以上の粘性を有するのが好ま しぐまたその上限としては 1.0 X 105 mPa' s以下であるのが好ましい。硬さとしては、 6 X 104 N/m2以下の硬さが好ましぐ 5 X 104 N/m2以下であるのがさらに好ましい。 [0027] The jelly-like food of the present invention is not particularly limited as long as it has a shape and physical properties similar to an elastic semi-solid, so-called jelly or jelly-like beverage. It is preferable to have a viscosity of 5.0 × 10 2 mPa ′s or more under the temperature condition at the time of ingestion, and the upper limit thereof is preferably 1.0 × 10 5 mPa ′s or less. The hardness is more preferably 5 × 10 4 N / m 2 or less, which is preferably 6 × 10 4 N / m 2 or less.
[0028] ここでいう粘度とは、「液体の流れ難さ、あるいは粘っこさの程度を示す物質定数」 で、これを粘性率あるいは粘度という。力を加えて流したときに、内部に摩擦を生じて 止まっていぐすなわち、押し流す力に抵抗する性質を粘性という。  The term “viscosity” as used herein means “a material constant indicating the difficulty of liquid flow or the degree of viscosity”, which is referred to as viscosity or viscosity. Viscosity is the property that resists the force of squeezing when friction is applied to the inside when it is applied.
[0029] ここでいう硬さとは、「一定速度で圧縮したときの抵抗」で、物質に外部から局部的 な力(集中荷重)を短時間に加えて、そのときに示される物質の変形度合力 変形に 対する抵抗の大小を判断してこれを硬さとしている。 [0030] 食品の粘度や硬さは、市販の粘度計(レオメーター、クリープメーター等)を用いて 測ることが出来る。 [0029] Hardness here refers to "resistance when compressed at a constant speed". When a local force (concentrated load) is applied to a substance from outside in a short time, the degree of deformation of the substance indicated at that time is shown. The strength of the resistance against the resultant deformation is determined as hardness. [0030] The viscosity and hardness of food can be measured using a commercially available viscometer (rheometer, creep meter, etc.).
[0031] さらに、本発明におけるゼリー状食品は、嚥下障害者向けの食品、栄養補助食品と しても使用すること力できる。高齢社会において、寝たきり'重度の痴呆'脳卒中後遺 症等、運動障害のある高齢者数も増加している。嚥下機能が障害されると、食物や 飲料を正常に飲み込めず、誤って気管に引き込んでしまう誤嚥 (ごえん)によって、窒 息死や誤嚥性肺炎の誘発と!/、つた危険性もある。健常者では水の様に低粘度の液 体がもっとも飲み込み易いが、嚥下困難者においてはとろみのある方がかえって誤 嚥を起こしにくいことが知られ、病院、特養ホーム等では液状食品に粘性を加えた食 品が用いられている。また、当然食材の硬さも重要であり、ある程度の柔らかさでない と、嚙み砕いたり、飲み混んだりすることが難しくなる。  [0031] Furthermore, the jelly-like food according to the present invention can be used as a food for dysphagia and as a dietary supplement. In an aging society, the number of elderly people with movement disorders such as bedridden 'severe dementia' and sequelae of stroke is increasing. If the swallowing function is impaired, food and beverages cannot be swallowed normally, and aspiration that is accidentally drawn into the trachea can lead to death of asphyxia and aspiration pneumonia! is there. It is known that a liquid with a low viscosity like water is most easily swallowed by healthy people, but it is known that a person who has difficulty swallowing is less likely to cause aspiration. Food is used. Naturally, the hardness of the food is also important, and if it is not soft enough, it will be difficult to knead and mix.
[0032] 日本厚生労働省では、粘度が 1.5 X 103 mPa' s以上、硬さ力 X 104 N/m2以下(舌 でつぶせる程度の硬さ)のものを、咀嚼 '嚥下困難者用食品の基準としていることから 、本発明のゼリー状食品を、これら基準を満たすように調整することによって、咀嚼- 嚥下困難者用食品として使用することが可能である。また、このようなゼリー状食品は 、幼児 ·老人向け食品用途にも好ましく利用できる。 [0032] According to the Ministry of Health, Labor and Welfare, foods with a viscosity of 1.5 X 10 3 mPa 's or more and a hardness force of 10 4 N / m 2 or less (hard enough to be crushed by the tongue) Therefore, by adjusting the jelly-like food of the present invention so as to satisfy these standards, it can be used as a food for persons with difficulty in chewing-swallowing. Moreover, such jelly-like food can be preferably used for food use for infants and the elderly.
[0033] 本発明のゼリー状食品において、 目的とする粘度や硬度に調整する方法としては 特に限定されず、ゲル化剤の種類や使用量を調整したり、適宜その他増粘剤などを 使用するなど公知の方法を用いることができる。また、咀嚼'嚥下困難者用食品用途 に適した粘度と硬さのゼリー状食品とするためには、例えば、ゲル化剤としてゼラチン と、寒天またはカラギーナンを併用する、あるいは、カラギーナンとキサンタンガムま たはネイティブジエランガムを併用するなどの方法が挙げられる。  [0033] In the jelly-like food of the present invention, the method for adjusting to the target viscosity and hardness is not particularly limited, and the type and amount of the gelling agent are adjusted, and other thickeners are used as appropriate. For example, a known method can be used. In addition, in order to make a jelly-like food with viscosity and hardness suitable for food use for chewing and difficult to swallow, for example, gelatin and agar or carrageenan are used as a gelling agent, or carrageenan and xanthan gum are used. The method includes using native dielan gum in combination.
[0034] 本発明のゼリー状食品には、抗酸化剤、有機酸、ビタミン類を添加しても良い。  [0034] An antioxidant, an organic acid, and vitamins may be added to the jelly-like food of the present invention.
[0035] 抗酸化剤としては、リコペン、カロテノイド類、フラボノイド類、ポリフエノール類、ダル タチオン、セレン、チォ硫酸ナトリウム、 αリポ酸およびその誘導体、ピクノジェノール 、フラバンジェノール、スーパーオキサイドデイスムターゼ(SOD)、グルタチオンペル ォキシダーゼ、ダルタチオン S トランスフェラーゼ、ダルタチオン還元酵素、力タラ ーゼ、ァスコルビン酸ペルォキシダーゼ、およびこれらの混合物などが挙げられる。こ れら抗酸化剤はュビキノールの酸化に対する安定性を高め、より安定した高い効果 を得る観点から特に好ましい添加物として使用される。 [0035] Antioxidants include lycopene, carotenoids, flavonoids, polyphenols, dartathione, selenium, sodium thiosulfate, alpha lipoic acid and its derivatives, pycnogenol, flavangenol, superoxide dismutase (SOD) Glutathione peroxidase, dartathione S transferase, dartathione reductase, force tarase, ascorbate peroxidase, and mixtures thereof. This These antioxidants are used as particularly preferred additives from the viewpoint of enhancing the stability of ubiquinol to oxidation and obtaining a more stable and high effect.
[0036] 有機酸としては、特に限定はされないが、例えば、クェン酸、クェン酸誘導体、酢酸 、乳酸、コハク酸、酒石酸、ァスパラギン酸、シユウ酸、リンゴ酸、マロン酸、フマル酸、 マレイン酸、プロピオン酸、酪酸、バレリン酸、イソクェン酸、およびこれらの混合物な ど力 S挙げられる。有機酸はそれ自体が体に有用な成分であるだけでなぐ本発明の ゼリー状食品に適度な風味を付加できる点で好ましい。  [0036] The organic acid is not particularly limited, but examples thereof include succinic acid, succinic acid derivatives, acetic acid, lactic acid, succinic acid, tartaric acid, aspartic acid, oxalic acid, malic acid, malonic acid, fumaric acid, maleic acid, Examples include propionic acid, butyric acid, valeric acid, isochenoic acid, and mixtures thereof. Organic acids are preferred in that they can add an appropriate flavor to the jelly-like food of the present invention, which is not only a component useful for the body itself.
[0037] ビタミン類としては特に限定されず、例えば、ビタミン A、ビタミン B (ビタミン Bl、ビタ ミン B1誘導体、ビタミン B2、ビタミン B6、ビタミン B12など)、ビタミン C、ビタミン D、ビ タミン£、ビタミン 、ビォチン、パントテン酸、ニコチン酸、およびこれらの混合物など が挙げられる。ここで、ビタミン B1誘導体には、チアミンまたはその塩、チアミンジスル フイド、フルスルチアミンまたはその塩、ジセチアミン、ビスブチチアミン、ビスベンチア ミン、ベンフォチアミン、チアミンモノフォスフェートジスルフイド、シコチアミン、オタトチ ァミン、プロスルチアミンなどのビタミン B1としての生理活性を有する化合物のすべて が含まれ得る。  [0037] The vitamins are not particularly limited. For example, vitamin A, vitamin B (vitamin Bl, vitamin B1 derivative, vitamin B2, vitamin B6, vitamin B12, etc.), vitamin C, vitamin D, vitamins, vitamins , Biotin, pantothenic acid, nicotinic acid, and mixtures thereof. Here, the vitamin B1 derivative includes thiamine or a salt thereof, thiamine disulfide, fursultiamine or a salt thereof, dicetiamine, bisbuthiamine, bisbentiamine, benfotiamine, thiamine monophosphate disulfide, chicotiamine, otato thiamine, All of the compounds having physiological activity as vitamin B1, such as prosultiamine, can be included.
[0038] これらの抗酸化物質、有機酸、ビタミン類は、 2種類以上を組み合わせても良い。  [0038] These antioxidants, organic acids, and vitamins may be used in combination of two or more.
[0039] 本発明のゼリー状食品に含まれる他の成分としては、食品に使用できる成分であ れば特に限定されず、必要に応じて、糖類、甘味料、果汁、フレーバー粉末、香料、 防腐剤、着色剤や保存剤などが使用できる。 [0039] Other ingredients contained in the jelly-like food of the present invention are not particularly limited as long as they are ingredients that can be used in foods. If necessary, sugars, sweeteners, fruit juices, flavor powders, flavors, antiseptics Agents, colorants, preservatives, etc. can be used.
[0040] 糖類としては特に限定されず、例えば、庶糖、ブドウ糖、果糖、乳糖、麦芽糖、異性 化糖、カップリングシュガー、パラチノース、ネオシュガー、還元澱粉糖化飴、キシロ ース、ソルボース、ラクッロース、ポリデキストロース等の水溶性糖類、およびこれらの 混合物などが挙げられる。 [0040] The saccharide is not particularly limited, and examples thereof include sucrose, glucose, fructose, lactose, maltose, isomerized sugar, coupling sugar, palatinose, neosugar, reduced starch saccharified starch, xylose, sorbose, lactulose, poly And water-soluble saccharides such as dextrose, and mixtures thereof.
[0041] 甘味料としては特に限定されず、例えば、サッカリンナトリウム、アスパルテーム、ス テビォサイド、ステビアエキス、パラメトキシシンナミックアルデヒド、ネオヘスペリジル ジヒドロカルコン、ペリラルチン、およびこれらの混合物などが挙げられる。 [0041] The sweetener is not particularly limited, and examples thereof include saccharin sodium, aspartame, stevioside, stevia extract, paramethoxycinnamic aldehyde, neohesperidyl dihydrochalcone, perilartin, and mixtures thereof.
[0042] 果汁としては特に限定されず、例えば、りんご果汁、オレンジ果汁、ぶどう果汁、メロ ン果汁、レモン果汁などが用いられる。 [0043] フレーバー粉末としては特に限定されず、例えば、コーヒー粉末、抹茶粉末、煎茶 粉末、ココア粉末などが用いられる。 [0042] The fruit juice is not particularly limited, and examples thereof include apple juice, orange juice, grape juice, melon juice, lemon juice and the like. [0043] The flavor powder is not particularly limited, and for example, coffee powder, matcha powder, sencha powder, cocoa powder and the like are used.
[0044] 香料としては特に限定されず、例えば、メントール、カルボン、ァネトール、シネオ一 ル、サリチル酸メチル、シンナミックアルデヒド、オイゲノール、 3 (1ーメントキシ)プ ロノ ンー 1 , 2—ジォ一ノレ、チモーノレ、リナローノレ、リナリーノレアセテート、 リモネン、メ ントン、メンチルアセテート、 N—置換 パラメンタン一 3—カルボキサミド、ビネン、ォ クチノレァノレデヒド、シトラール、プレゴン、カルビールアセテート、ァニスアルデヒド、ェ チルアセテート、ェチルブチレート、ァリルシクロへキサンプロピオネート、メチルアン スラニレート、ェチノレメチノレエチニノレグリシデート、ノ ニリン、ゥンデカラクトン、へキサ ナーノレ、 ェチノレアノレコーノレ、プロピノレアノレコーノレ、ブタノーノレ、イソアミノレァノレコーノレ 、へキセノール、ジメチルサルファイド、シクロテン、フルフラール、トリメチルビラゾン、 ェチルラタテート、ェチルチオアセテートなどの単品香料、更に、ペパーミント油、ス ペアミント油、ァニス油、ユーカリ油、ウィンターグリーン油、カシア油、クローブ油、タ ィム油、セージ油、レモン油、オレンジ油、ハツ力油、カルダモン油、コリアンダー油、 マンダリン油、ライム油、ラベンダー油、ローズマリー油、ローレノレ油、力モミ一ノレ油、 キャラウェイ油、マジョラム油、べィ油、レモングラス油、ォリガナム油、パインニードル 油、ネロリ油、ローズ油、ジャスミン油、イリスコンクリート、アブソリユートペパーミント、 アブソリュートローズ、オレンジフラワーなどの天然香料、ストロベリーフレーバー、ァ ップノレフレーノ一、ノ ナナフレーノ一、ノ ィナップノレフレーノ一、グレープフレーノ 一、マンゴーフレーノ一、ノ ターフレーノ一. ミノレ々フレーノ一、フノレーッミックスフレ 一バー、トロピカルフルーツフレーバーなどの調合香料、およびこれらの混合物など が挙げられる。  [0044] The fragrance is not particularly limited, and examples thereof include menthol, carvone, vanetol, cineol, methyl salicylate, cinnamic aldehyde, eugenol, 3 (1-menthoxy) pronone 1, 2-dionole, and chimole. , Linalool, linalino acetate, limonene, menton, menthyl acetate, N-substituted paramentan 1-carboxamide, vinylene, octanolenodehydride, citral, pregon, carbyl acetate, anisaldehyde, ethyl acetate, ethyl butyrate , Allylcyclohexanepropionate, methylanthranilate, ethinoremethinoreethino glycidate, nonylin, undecalactone, hexananol, ethinoreanoreconole, propinoreanoreconole, butanol Single-flavored products such as soaminoleanolecole, hexenol, dimethylsulfide, cycloten, furfural, trimethylvirazone, ethyllatatate, ethylthioacetate, peppermint oil, spearmint oil, anise oil, eucalyptus oil, wintergreen oil , Cassia oil, Clove oil, Time oil, Sage oil, Lemon oil, Orange oil, Heart force oil, Cardamom oil, Coriander oil, Mandarin oil, Lime oil, Lavender oil, Rosemary oil, Lorenole oil, Power fir Natural oil such as oil, caraway oil, marjoram oil, bay oil, lemongrass oil, oliganum oil, pine needle oil, neroli oil, rose oil, jasmine oil, Iris concrete, absolute peppermint, absolute rose, orange flower Fragrance, straw Believe Flavor, Ap Nore Freno, Nonana Freno, Nonap No Le Freno, Grape Freno, Mango Freno, Notter Flano. Minore Le Freno, Funolex Mix Flavor, Tropical Fruit Flavor, etc. Fragrances, and mixtures thereof.
[0045] 防腐剤としては特に限定されず、例えば、アミノエチルスルホン酸、安息香酸、安息 香酸ナトリウム、エタノール、ェデト酸ナトリウム、カンテン、 dl—カンフル、クェン酸、ク ェン酸ナトリウム、サリチル酸、サリチル酸ナトリウム、サリチル酸フエニル、ジブチルヒ ドロキシトルエン、ソルビン酸、ソルビン酸カリウム、窒素、デヒドロ酢酸、デヒドロ酢酸 ナトリウム、 2—ナフトール、 白糖、ハチミツ、パラォキシ安息香酸イソブチル、パラオ キシ安息香酸イソプロピル、パラォキシ安息香酸ェチル、パラォキシ安息香酸ブチル 、パラォキシ安息香酸プロピル、パラォキシ安息香酸メチル、 1 メントール、ユーカリ 油、およびこれらの混合物などが挙げられる。 [0045] The preservative is not particularly limited, and examples thereof include aminoethylsulfonic acid, benzoic acid, sodium benzoate, ethanol, sodium edetate, agar, dl-camphor, citrate, sodium citrate, salicylic acid, Sodium salicylate, phenyl salicylate, dibutylhydroxytoluene, sorbic acid, potassium sorbate, nitrogen, dehydroacetic acid, sodium dehydroacetate, 2-naphthol, sucrose, honey, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, ethyl paraoxybenzoate , Butyl paraoxybenzoate Propyl parabenzoate, methyl paraoxybenzoate, 1 menthol, eucalyptus oil, and mixtures thereof.
[0046] 着色剤としては特に限定されず、食品に添加することが許可されているものなどを 使用すること力でき、例えば、青色 1号、黄色 4号、緑色 3号、赤色 5号、レーキ色素、 二酸化チタン、赤キャベツ色素、紅麹色素、ムラサキイモ色素、クチナシ色素、コチニ ール色素、カラメル色素、クロロフィル、およびこれらの混合物などが挙げられる。  [0046] The colorant is not particularly limited, and it is possible to use one that is permitted to be added to food, for example, Blue No. 1, Yellow No. 4, Green No. 3, Red No. 5, Lake Examples thereof include dyes, titanium dioxide, red cabbage dyes, red potato dyes, purple potato dyes, gardenia dyes, cochineal dyes, caramel dyes, chlorophylls, and mixtures thereof.
[0047] 保存剤としては特に限定されず、例えば、安息香酸、安息香酸ナトリウム、エタノー ノレ、ェデト酸ナトリウム、乾燥亜硫酸ナトリウム、クェン酸、グリセリン、サリチル酸、サリ チル酸ナトリウム、ジブチルヒドロキシトルエン、 D ソルビトール、ソルビン酸、ソルビ ン酸カリウム、デヒドロ酢酸ナトリウム、ノ ラオキシ安息香酸イソプチル、ノ ラオキシ安 息香酸イソプロピル、パラォキシ安息香酸ェチル、パラォキシ安息香酸ブチル、パラ ォキシ安息香酸プロピル、パラォキシ安息香酸メチル、プロピレングリコール、リン酸 、およびこれらの混合物などが挙げられる。  [0047] The preservative is not particularly limited. For example, benzoic acid, sodium benzoate, ethanol, sodium edetate, dried sodium sulfite, citrate, glycerin, salicylic acid, sodium salicylate, dibutylhydroxytoluene, D sorbitol , Sorbic acid, potassium sorbate, sodium dehydroacetate, isoptyl noroxybenzoate, isopropyl noroxybenzoate, ethyl parabenzoate, butyl parabenzoate, propyl parabenzoate, methyl paraoxybenzoate, propylene glycol , Phosphoric acid, and mixtures thereof.
[0048] また、本発明のゼリー状食品には、若干量の油脂成分を含んでいてもかまわない  [0048] The jelly-like food of the present invention may contain a slight amount of fat and oil components.
1S カロリーを低く抑えるという目的の場合はその使用量は少ないほど好ましぐその 観点からは油脂の使用量は、食品全体量に対し 10重量%以下であるのが好ましぐ 5重量%以下であるのがより好ましぐ 1重量%以下であるのがさらに好ましぐ 0. 5重 量%未満であるのが特に好ましい。通常、一般食品やサプリメントにおいて、ュビキノ 一ルを製剤や食品中に可溶化あるいは分散させるために、ュビキノールよりも大過剰 量の油脂が使用される力 本発明のゼリー状食品においては、ゼリー状とすることで 好適にュビキノールを食品中分散させることが可能なため、食品中のュビキノールに 対する油脂の含有量を例えば等量以下、さらには半分以下とすることもでき、油脂を 実質的にあるレヽはまったく含まな!/、ことも可能である。  For the purpose of keeping 1S calorie low, the less the amount used, the better. From the viewpoint, the amount of fat used is preferably 10% by weight or less, and preferably 5% by weight or less, based on the total amount of food. More preferably, it is 1% by weight or less, more preferably less than 0.5% by weight. In general foods and supplements, the ability to use a larger excess of oil than ubiquinol in order to solubilize or disperse ubiquinol in pharmaceutical preparations and foods. Thus, ubiquinol can be suitably dispersed in the food, so that the content of fat and oil relative to ubiquinol in the food can be, for example, equal or less, and even less than half. Is not included at all!
[0049] 本発明のゼリー状食品は、一般食品として、また栄養補助食品、健康食品として、 健常者のみならず、高齢者や何らかの疾患を有している病人に、ュビキノールを補 給しうる低カロリー食品として摂取できる。さらには、また、嚥下障害を有する高齢者 や病人に対する補助食品としても有用である。さらには、従来のカプセル摂取が困難 であったペットなどの動物への応用も可能である。その形態としては、例えばカップ等 に装填されたゼリーとして、あるいはバウチ等に充填されたゼリー状飲料として提供さ れる他、使用者側で加水及び/又は加熱などの調理を行うことで、ゼリー状とするこ とができる粉末 ·固形形態として提供される。 [0049] The jelly-like food of the present invention is a general food, as a dietary supplement and a health food, and is low in ubiquinol for not only healthy subjects but also elderly people and sick people with some disease. Can be consumed as a calorie food. Furthermore, it is also useful as a supplement for elderly and sick people with dysphagia. Furthermore, it can also be applied to animals such as pets, which have been difficult to consume in the past. As its form, for example, a cup or the like In addition to being provided as a jelly loaded in a bag or as a jelly-like beverage filled in a bouch or the like, the user can also prepare a jelly-like powder by cooking such as water and / or heating. Provided as a solid form.
[0050] 本発明のゼリー状食品の摂取量としては特に限定されないが、成人 1日あたり、ュ ビキノーノレ量として lmg〜; !OOOmg、好ましくは 10mg〜500mg、さらに好ましくは 3 0mg〜300mgでめる。 [0050] The amount of the jelly-like food of the present invention is not particularly limited, but the daily dose for adults is lmg to;! OOOmg, preferably 10mg to 500mg, more preferably 30mg to 300mg. .
実施例  Example
[0051] 以下に実施例を揚げて本発明を更に詳しく説明するが、本発明はこれら実施例の みに限定されるものではない。尚、純度及びュビキノール/ュビキノンの比率(重量 比)は上記 HPLC分析により求めた。  [0051] Hereinafter, the present invention will be described in more detail with reference to examples. However, the present invention is not limited to these examples. The purity and the ubiquinol / ubiquinone ratio (weight ratio) were determined by the above HPLC analysis.
[0052] (製造例 1 )ュビキノールの製造  [0052] (Production Example 1) Production of ubiquinol
lOOOgのエタノーノレ中 ίこ、 lOOgのュヒ、、キノン(純度 99. 4%) , 60gの L ァスコノレ ビン酸を加え、 78°Cにて攪拌し、還元反応を行った。 30時間後、 50°Cまで冷却し、 同温を保持しながらエタノール 330gと水 70gを添加した。このエタノール溶液(ュビ キノール lOOgを含む)を攪拌しながら、 10°C/時間の冷却速度で 2°Cまで冷却し、 白色のスラリーを得た。得られたスラリーを減圧濾過し、湿結晶を冷エタノール、冷水 、冷エタノールで順に洗浄 (洗浄に用いた冷溶媒の温度は 2°C)して、さらに湿結晶 を減圧乾燥(20〜40°C、;!〜 30mmHg)することにより、白色の乾燥結晶 97gを得た 。減圧乾燥を除く全ての操作は窒素雰囲気下で実施した。  A lOOOOg ethanol solution, lOOg liquor, quinone (purity 99.4%) and 60 g L-asconolevic acid were added, and the mixture was stirred at 78 ° C. to carry out a reduction reaction. After 30 hours, the mixture was cooled to 50 ° C, and 330 g of ethanol and 70 g of water were added while maintaining the same temperature. While stirring this ethanol solution (containing ubiquinol lOOg), it was cooled to 2 ° C. at a cooling rate of 10 ° C./hour to obtain a white slurry. The obtained slurry was filtered under reduced pressure, and the wet crystals were washed with cold ethanol, cold water and cold ethanol in this order (the temperature of the cold solvent used for washing was 2 ° C), and the wet crystals were further dried under reduced pressure (20-40 ° C). C,;! To 30 mmHg) to obtain 97 g of white dry crystals. All operations except drying under reduced pressure were performed under a nitrogen atmosphere.
[0053] (製造例 2)ュビキノールの製造  [Production Example 2] Production of ubiquinol
lOOgのュビキノン(純度 99. 4%)を 25°Cで lOOOgのヘプタン溶液に溶解させた。 攪拌しながら、還元剤として次亜硫酸ナトリウム(純度 75%以上) lOOgに 1000mlの 水を加えて溶解させた水溶液を徐々に添加し、 25°C、 pH4〜6で還元反応を行った 。 2時間後、反応液から水相を除去し、脱気した飽和食塩水 lOOOgでヘプタン相を 6 回水洗した。以上、すべての操作は窒素雰囲気下で実施した。このヘプタン相を減 圧下にて溶媒置換し、 50°Cのュビキノールの 7% (w/w)エタノール溶液を調製した (ュビキノールを lOOg含む)。このエタノール溶液に水 50gを添カロし、攪拌しながら、 10°C/時間の冷却速度で 2°Cまで冷却して結晶を析出させた。全ての操作は窒素 雰囲気下で実施した。得られたスラリーを減圧濾過し、湿結晶を冷エタノール、冷水lOOg ubiquinone (purity 99.4%) was dissolved in lOOOg heptane solution at 25 ° C. While stirring, sodium hyposulfite (purity of 75% or more) as a reducing agent was gradually added an aqueous solution prepared by adding 1000 ml of water to lOOg, and a reduction reaction was performed at 25 ° C and pH 4-6. After 2 hours, the aqueous phase was removed from the reaction solution, and the heptane phase was washed 6 times with degassed saturated saline lOOOg. As described above, all operations were performed in a nitrogen atmosphere. This heptane phase was subjected to solvent replacement under reduced pressure to prepare a 7% (w / w) ethanol solution of ubiquinol at 50 ° C (containing lOOg of ubiquinol). 50 g of water was added to the ethanol solution, and while stirring, the solution was cooled to 2 ° C. at a cooling rate of 10 ° C./hour to precipitate crystals. All operations are nitrogen Performed under atmosphere. The obtained slurry was filtered under reduced pressure, and the wet crystals were cooled with cold ethanol and cold water.
、冷エタノールで順に洗浄 (洗浄に用いた冷溶媒の温度は 2°C)して、さらに、湿結晶 を減圧乾燥(20〜40°C、;!〜 30mmHg)することにより、白色の乾燥結晶 97gを得たNext, wash with cold ethanol (the temperature of the cold solvent used for washing is 2 ° C), and dry the wet crystals under reduced pressure (20-40 ° C;! -30mmHg) to obtain white dry crystals. Obtained 97g
Yes
[0054] (実施例 1 )ゼリー状食品の製造  [Example 1] Production of jelly-like food
400gの水にゼラチン(新田ゼラチン株式会社製;タイプ R) 20gを加え、 70°Cにて ゼラチンを溶解させた。同温を維持しながら、製造例 1で得られた 5gのュビキノール を加え、ュビキノールが完全に融解した後、 TKホモミキサー MarkII2. 5型(プライミ タス株式会社製)を用い、 5分間(lOOOOrpm)乳化させた。この乳化液を室温まで冷 却させた後、さらに、冷蔵庫 (4°C)にて 2時間冷却することにより、ュビキノールを含 有するゼリーを調製した。得られたゼリーは均一で、ゼリー中ュビキノールが析出す ることなく良好に分散していた。 20 g of gelatin (Nitta Gelatin Co., Ltd .; type R) was added to 400 g of water, and gelatin was dissolved at 70 ° C. While maintaining the same temperature, add 5 g of ubiquinol obtained in Production Example 1 and completely melt the ubiquinol, then use TK homomixer MarkII2.5 type 5 (manufactured by Primitas Co., Ltd.) for 5 minutes (lOOOOrpm) Emulsified. After cooling this emulsion to room temperature, it was further cooled in a refrigerator (4 ° C.) for 2 hours to prepare a jelly containing ubiquinol. The obtained jelly was uniform and dispersed well without precipitation of ubiquinol in the jelly.
Figure imgf000014_0001
Figure imgf000014_0001
<サンプル調製〉  <Sample preparation>
動物試験のため、ュビキノールを含有するゼリー状食品を乾燥させたモデルサンプ ルを以下のようにして調製した。  For animal testing, a model sample obtained by drying a jelly-like food containing ubiquinol was prepared as follows.
[0056] 160gの蒸留水に、ゼラチン(新田ゼラチン株式会社製; APH— 250) 40gを 60°C で溶解させ、ゼラチン水溶液を作成した。この水溶液を 60°Cに加温後、上記製造例 1で得られたュビキノール粉末 6. 2gを添加して溶融させた後、 TKホモミキサー Mar kll (プライミクス株式会社製)で 10000回転 X 5分間乳化し、水中油型乳化組成物を 得た。ここで得た水中油型乳化組成物 75gを、あらかじめ 90°Cに加熱しておいた、 M CT (理研ビタミン社製;アクター M— 2) 145gおよび界面活性剤(ポリグリセリン縮合リ シノール酸エステル:阪本薬品工業株式会社製; SYグリスター CRS— 75) 5gからな る油性成分に添加し、攪拌及び懸濁液の温度を 105°Cに調整することで、水分を蒸 発させた。その後は、常法に従って、固液分離により油性成分をろ別し、約 500gの エタノールで粒子に付着した油性成分を洗浄 ·除去後、 50°Cで乾燥して、ュビキノー ルがゼラチン中に分散した粒子状組成物(ゼリー状食品のモデルサンプル)を得た。 この組成物および製造例 1のュビキノール結晶(粉末そのまま)を、それぞれラット用 カプセルに詰めて評価サンプルとした。 [0056] In 160 g of distilled water, 40 g of gelatin (manufactured by Nitta Gelatin Co., Ltd .; APH-250) was dissolved at 60 ° C to prepare an aqueous gelatin solution. After heating this aqueous solution to 60 ° C, 6.2 g of the ubiquinol powder obtained in Production Example 1 above was added and melted, and then 10000 rotations x 5 minutes with TK homomixer Mar kll (manufactured by Primics Co., Ltd.) Emulsification was performed to obtain an oil-in-water emulsion composition. 75 g of the oil-in-water emulsion composition obtained here was heated to 90 ° C in advance, 145 g of M CT (manufactured by Riken Vitamin Co., Ltd .; Actor M-2) and surfactant (polyglycerin condensed ricinoleic acid ester) : Sakamoto Yakuhin Kogyo Co., Ltd .; SY Glyster CRS-75) Water was evaporated by adding to 5 g of oil component and adjusting the temperature of stirring and suspension to 105 ° C. After that, oily components are separated by solid-liquid separation according to a conventional method, and the oily components adhering to the particles are washed and removed with about 500 g of ethanol, dried at 50 ° C, and ubiquinol is dispersed in gelatin. A particulate composition (model sample of jelly-like food) was obtained. This composition and the ubiquinol crystals of Production Example 1 (as powders) were used for rats respectively. An evaluation sample was packed in a capsule.
[0057] <実験系〉  [0057] <Experimental system>
8週齢の雄性 Sprague— Dawleyラット(ブリーダーまたは入手元:日本エスエルシ 一株式会社)に上記に記載の被験物質をュビキノールとして 10mg/kgの用量で、 カプセル用ゾンデを用いて経口投与した(各サンプル N= 5)。被験物質投与 1、 2、 4 、 8、および 24時間後に各ラットより血液を採取した。採取した血液を遠心分離し、血 漿を得た。その後、血漿中のュビキノールの酸化処理、およびュビキノンの抽出処理 を行い、 HPLCを用いてュビキノンの濃度を測定した。  8-week-old male Sprague-Dawley rats (Bleeder or source: Nippon SLC Co., Ltd.) were orally administered with the test substance described above as ubiquinol at a dose of 10 mg / kg using a capsule sonde (each sample) N = 5). Blood was collected from each rat 1, 2, 4, 8, and 24 hours after administration of the test substance. The collected blood was centrifuged to obtain plasma. Thereafter, oxidation treatment of ubiquinol in plasma and extraction treatment of ubiquinone were performed, and the concentration of ubiquinone was measured using HPLC.
[0058] 以下に、ュビキノールパルク、またはュビキノールとゼラチンを含む組成物(被験物 質)を経口投与した後の血漿中ュビキノン最高血中濃度 (Cmax)と被験物質投与 24 時間後までの血漿中ュビキノン濃度の経時変化曲線下面積 (AUC)値を示す。  [0058] The following is the maximum plasma concentration of ubiquinone (Cmax) after oral administration of ubiquinol parc or a composition containing ubiquinol and gelatin (test substance) and plasma up to 24 hours after administration of the test substance. The area under the time course curve of the concentration of ubiquinone (AUC) is shown.
[0059] [表 1]
Figure imgf000015_0001
[0059] [Table 1]
Figure imgf000015_0001
[0060] ュビキノール結晶と、ゼラチン中にュビキノールが分散した組成物の経口投与後の 血漿中ュビキノン濃度を比較すると、ゼラチン中にュビキノールが分散した組成物の 方が高い血漿中濃度を示し、また、 AUCも高いことが示された。すなわち、ゼラチン 中にュビキノールを共存させると吸収性が向上することが明らかとなった。 [0060] Comparing the plasma ubiquinol concentration after oral administration of ubiquinol crystals and a composition in which ubiquinol was dispersed in gelatin, the composition in which ubiquinol was dispersed in gelatin showed a higher plasma concentration, AUC was also shown to be high. That is, it was revealed that the absorption is improved when ubiquinol is allowed to coexist in gelatin.
[0061] (言周 ゼリー 口口口  [0061] (Kang Zhou Jelly mouth mouth mouth
ゼラチンに加水 ·加熱を行つて溶解させた後、製造例 1で得たュビキノールを加え てホモジナイズし、ュビキノール可溶物(乳化物)を得た。次に、先の乳化物にカゼィ ン及びデキストリンを加えながら加熱し、さらに、果糖ぶどう糖液糖、乳酸 Ca、クェン 酸、香料、クェン酸 Na、ビタミン類を加えて、十分攪拌しながらカップ状容器に充填 することによって、ュビキノールを含有したゼリー状食品を得た。得られたゼリー状食 品の味は良好であった。  After water was heated and dissolved in gelatin, ubiquinol obtained in Production Example 1 was added and homogenized to obtain a ubiquinol-soluble material (emulsion). Next, heat while adding casein and dextrin to the previous emulsion, and add fructose-glucose liquid sugar, calcium lactate, citrate, fragrance, citrate Na, vitamins, and a cup-shaped container with sufficient stirring. The jelly-like food containing ubiquinol was obtained. The taste of the resulting jelly-like food was good.
[0062] (調製例 2)ゼリー状食品  [Preparation Example 2] Jelly-like food
ゼラチンに加水 ·加熱を行つて溶解させた後、製造例 1で得たュビキノールを加え てホモジナイズし、ュビキノール可溶物(乳化物)を得た。次に、先の乳化物にカゼィ ン及びデキストリンを加えながら加熱し、さらに、果糖ぶどう糖液糖、乳酸 Ca、クェン 酸、香料、クェン酸 Na、ビタミン類を加えて、十分攪拌しながらアルミ複合シートから 形成されたバウチに充填密封することによって、ュビキノールを含有したゼリー状食 品を得た。得られたゼリー状食品の味は良好であった。 Add water and heat to gelatin to dissolve it, then add ubiquinol obtained in Production Example 1. To obtain a ubiquinol-soluble material (emulsion). Next, heat while adding casein and dextrin to the above emulsion, and add fructose-glucose liquid sugar, calcium lactate, citrate, fragrance, sodium citrate, and vitamins, and mix well with stirring. A jelly-like food containing ubiquinol was obtained by filling and sealing the bouch formed from the above. The taste of the obtained jelly-like food was good.

Claims

請求の範囲 The scope of the claims
[1] ュビキノールを含有するゼリー状食品。 [1] A jelly-like food containing ubiquinol.
[2] ゼリー状とするためのゲル化剤を使用することを特徴とする請求項 1記載のゼリー状 ロ P  [2] A gelling agent according to claim 1, characterized by using a gelling agent for making a jelly.
[3] ゲル化剤として、寒天、ゼラチン、コンニヤク粉、ぺクチン、片栗でんぷん、葛でんぷ ん、蕨でんぷん(わらびこ)、タピオ力でんぷん及びカラギーナンからなる群より選択さ れる 1種以上のゲル化剤を使用することを特徴とする請求項 1又は 2記載のゼリー状 [3] As a gelling agent, at least one selected from the group consisting of agar, gelatin, konjac flour, pectin, starch starch, katsu starch, bran starch, tapio force starch and carrageenan A gelling agent according to claim 1 or 2, wherein a gelling agent is used.
^ PP o ^ PP o
[4] 粘度が 5.0 X 102 1·0 Χ 105 mPa' s、及び/又は、硬さ力 5 X 104 N/m2以下である 請求項;!〜 3いずれか 1項記載のゼリー状食品。 [4] The jelly according to any one of claims 1 to 3, wherein the viscosity is 5.0 X 10 2 1 · 0 硬 10 5 mPa's and / or the hardness force is 5 X 10 4 N / m 2 or less. Food.
[5] さらに有機酸を含有する請求項;!〜 4いずれか 1項記載のゼリー状食品。 [5] The jelly-like food according to any one of claims 4 to 6, further comprising an organic acid.
[6] さらに抗酸化剤を含有する請求項;!〜 5いずれか 1項記載のゼリー状食品。 [6] The jelly-like food according to any one of claims 5 to 5, further comprising an antioxidant.
[7] さらにビタミン類を含有する請求項 1 6いずれ力、 1項記載のゼリー状食品。 [7] The jelly-like food according to claim 1, further comprising vitamins.
[8] 油脂の含有量が 0. 5重量%未満である請求項;!〜 7いずれか 1項記載のゼリー状 ロ P [8] The jelly form according to any one of claims 1 to 7, wherein the fat content is less than 0.5% by weight.
PCT/JP2007/068350 2006-09-22 2007-09-21 Jelly-like food containing ubiquinol WO2008035757A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008535395A JPWO2008035757A1 (en) 2006-09-22 2007-09-21 Jelly-like food containing ubiquinol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006257240 2006-09-22
JP2006-257240 2006-09-22

Publications (1)

Publication Number Publication Date
WO2008035757A1 true WO2008035757A1 (en) 2008-03-27

Family

ID=39200580

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/068350 WO2008035757A1 (en) 2006-09-22 2007-09-21 Jelly-like food containing ubiquinol

Country Status (2)

Country Link
JP (1) JPWO2008035757A1 (en)
WO (1) WO2008035757A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009041449A1 (en) * 2007-09-25 2009-04-02 Kaneka Corporation Antiobesity agent
GB2494475A (en) * 2011-09-12 2013-03-13 Works With Water Nutraceuticals Ltd A nutraceutical supplement and method of making
JP2013111064A (en) * 2011-11-30 2013-06-10 Q P Corp Bottled liquid seasoning containing grated radish
WO2014188861A1 (en) * 2013-05-20 2014-11-27 ユーハ味覚糖株式会社 Gel-like composition having high ubiquinol content
JP2014226050A (en) * 2013-05-20 2014-12-08 ユーハ味覚糖株式会社 Manufacturing method of reduction type coenzyme q10-containing gummy candy, and gummy candy obtained by the manufacturing method
JP2015029452A (en) * 2013-08-01 2015-02-16 江崎グリコ株式会社 Frozen jelly
JP2015105243A (en) * 2013-11-29 2015-06-08 ユーハ味覚糖株式会社 Ubiquinol-containing liquid composition
JP2015104342A (en) * 2013-11-29 2015-06-08 ユーハ味覚糖株式会社 Gel composition with high content of ubiquinol
JPWO2013132670A1 (en) * 2012-03-05 2015-07-30 テルモ株式会社 Semi-solidified nutrient
JP2015209398A (en) * 2014-04-25 2015-11-24 ユーハ味覚糖株式会社 High absorption type ubiquinol formulation

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01206960A (en) * 1988-02-16 1989-08-21 Takenori Kato Gelatinous substance
JPH03224452A (en) * 1990-01-31 1991-10-03 Kyokuto Internatl Corp Chestnut-like food
JPH0630714A (en) * 1992-07-20 1994-02-08 Meiji Seika Kaisha Ltd Preparation of jelly dough
JP2002218917A (en) * 2001-01-23 2002-08-06 Sanei Gen Ffi Inc Gel composition comprising dispersed insoluble solid material and application thereof
JP2002255846A (en) * 2001-02-26 2002-09-11 Sunstar Inc Oral composition
JP2003504479A (en) * 1999-07-12 2003-02-04 コグニス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト Preparations without crosslinker
WO2003061395A1 (en) * 2002-01-18 2003-07-31 Kaneka Corporation Ubiquinol-enriched fat-containing foods
JP2004173678A (en) * 2002-09-30 2004-06-24 Morinaga & Co Ltd Low water-releasing gel-like composition and method for producing the same
JP2005143380A (en) * 2003-11-14 2005-06-09 Domo Corporation:Kk Nutritional food using snapping turtle egg
JP2005143365A (en) * 2003-11-13 2005-06-09 Toshihiro Nomura Food formulated with fat-soluble effective component
WO2005097091A1 (en) * 2004-04-09 2005-10-20 Kaneka Corporation Composition comprising reduced-form coenzyme q10 and carotenoid compound
JP2005328803A (en) * 2004-05-21 2005-12-02 Towa Kagaku Kk Vitality-promoting and aging-preventing food and method for producing the same
JP2006022064A (en) * 2004-07-09 2006-01-26 Asahi Kasei Pharma Kk Prophylactic and/or ameliorative agent for arteriosclerosis, functional food, or cosmetic
JP2006070016A (en) * 2004-08-02 2006-03-16 Kaneka Corp Whitening composition containing reduced coenzyme q

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01206960A (en) * 1988-02-16 1989-08-21 Takenori Kato Gelatinous substance
JPH03224452A (en) * 1990-01-31 1991-10-03 Kyokuto Internatl Corp Chestnut-like food
JPH0630714A (en) * 1992-07-20 1994-02-08 Meiji Seika Kaisha Ltd Preparation of jelly dough
JP2003504479A (en) * 1999-07-12 2003-02-04 コグニス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト Preparations without crosslinker
JP2002218917A (en) * 2001-01-23 2002-08-06 Sanei Gen Ffi Inc Gel composition comprising dispersed insoluble solid material and application thereof
JP2002255846A (en) * 2001-02-26 2002-09-11 Sunstar Inc Oral composition
WO2003061395A1 (en) * 2002-01-18 2003-07-31 Kaneka Corporation Ubiquinol-enriched fat-containing foods
JP2004173678A (en) * 2002-09-30 2004-06-24 Morinaga & Co Ltd Low water-releasing gel-like composition and method for producing the same
JP2005143365A (en) * 2003-11-13 2005-06-09 Toshihiro Nomura Food formulated with fat-soluble effective component
JP2005143380A (en) * 2003-11-14 2005-06-09 Domo Corporation:Kk Nutritional food using snapping turtle egg
WO2005097091A1 (en) * 2004-04-09 2005-10-20 Kaneka Corporation Composition comprising reduced-form coenzyme q10 and carotenoid compound
JP2005328803A (en) * 2004-05-21 2005-12-02 Towa Kagaku Kk Vitality-promoting and aging-preventing food and method for producing the same
JP2006022064A (en) * 2004-07-09 2006-01-26 Asahi Kasei Pharma Kk Prophylactic and/or ameliorative agent for arteriosclerosis, functional food, or cosmetic
JP2006070016A (en) * 2004-08-02 2006-03-16 Kaneka Corp Whitening composition containing reduced coenzyme q

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009041449A1 (en) * 2007-09-25 2009-04-02 Kaneka Corporation Antiobesity agent
GB2494475A (en) * 2011-09-12 2013-03-13 Works With Water Nutraceuticals Ltd A nutraceutical supplement and method of making
JP2013111064A (en) * 2011-11-30 2013-06-10 Q P Corp Bottled liquid seasoning containing grated radish
JPWO2013132670A1 (en) * 2012-03-05 2015-07-30 テルモ株式会社 Semi-solidified nutrient
WO2014188861A1 (en) * 2013-05-20 2014-11-27 ユーハ味覚糖株式会社 Gel-like composition having high ubiquinol content
JP2014226050A (en) * 2013-05-20 2014-12-08 ユーハ味覚糖株式会社 Manufacturing method of reduction type coenzyme q10-containing gummy candy, and gummy candy obtained by the manufacturing method
US9757332B2 (en) 2013-05-20 2017-09-12 Uha Mikakuto Co., Ltd. Gel-like composition having high ubiquinol content
JP2015029452A (en) * 2013-08-01 2015-02-16 江崎グリコ株式会社 Frozen jelly
JP2015105243A (en) * 2013-11-29 2015-06-08 ユーハ味覚糖株式会社 Ubiquinol-containing liquid composition
JP2015104342A (en) * 2013-11-29 2015-06-08 ユーハ味覚糖株式会社 Gel composition with high content of ubiquinol
JP2015209398A (en) * 2014-04-25 2015-11-24 ユーハ味覚糖株式会社 High absorption type ubiquinol formulation

Also Published As

Publication number Publication date
JPWO2008035757A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
WO2008035757A1 (en) Jelly-like food containing ubiquinol
JP5147239B2 (en) Coenzyme Q10-containing emulsion composition
JP4842824B2 (en) Coenzyme Q10-containing composition
JP6581902B2 (en) Therapeutic and / or preventive agent or method for promoting energy consumption and / or reducing energy consumption function
WO2007037249A1 (en) Cellooligosaccharide-containing composition
EP1755683A2 (en) Water-soluble coenzyme q10 inclusion complex with beta-cyclodextrin, process of preparing, and use thereof
CN105431057A (en) Methods of maintaining and improving muscle function
WO2006112283A1 (en) Anti-fatigue agent
JPWO2003077895A1 (en) Diabetes composition
JP5705898B2 (en) Liver function improving agent
KR20140021988A (en) Metal ion nanoclusters
JPWO2007013556A1 (en) Cancer prevention composition
BR112017005611B1 (en) ENERGY SUPPLY AGENT, SACARIDIC COMPOSITION, FOOD OR DRINK PRODUCT, AGENT FOR USE IN THE TREATMENT AND PREVENTION OF A DISEASE OR A SYMPTOM, AND USE OF A SACARIDIC COMPOSITION
JP2009137916A (en) Obesity amelioration composition
JP5103374B2 (en) Cardiac dysfunction improving agent or cardiac function maintaining agent
JP6456032B2 (en) Sirt1 activator and use of the Sirt1 activator
JP7044306B2 (en) Leucine blood concentration increase promoter and its uses
JPH09309840A (en) Agent for alopecia
JPWO2004080469A1 (en) Supplements for recovery of hypoglycemia symptoms
JP2013192514A (en) Method for manufacturing oyster extract
JP2015003873A (en) Adiponectin production promoter
JP2012206964A (en) PPAR-α ACTIVITY REGULATING AGENT
JP2009051751A (en) Muscle cell sugar transport promotion action composition
JP2004292355A (en) Anti-stress agent
JP4089874B2 (en) Coenzyme Q10-containing beverage

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07807700

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008535395

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07807700

Country of ref document: EP

Kind code of ref document: A1